Navigation Links
Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Date:5/8/2008

and 25 years old.(5) Bipolar disorder is the sixth leading cause of disability in the world.(3) About half of the patients with bipolar disorder who recover in response to treatment experience recurrence two years later.(6)

About Schizophrenia

Schizophrenia is a chronic, disabling brain disorder characterized by hallucinations, delusions, and disordered thinking. About 24 million people worldwide (or seven in every 1,000 adults in the population) have schizophrenia,(7) including more than two million people in the U.S.(8) and more than four million people in Europe.(9) People with schizophrenia may hear voices other people don't hear or may believe others are trying to harm them. As a result, they may become socially withdrawn, fearful, and agitated.(8)

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the development of, and potential market for, asenapine. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
2. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
3. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
4. New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia
5. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2008)...IELD, Ill., May 8 /- Siemen...(R) Holdings (LabCorp(R)) today announced,that the...s future,possibilities to co-develop new clinical ...tics, metabolic syndrome, oncology and diabetes. U... on developing new tests that,could make the bigge...
(Date:5/8/2008)...AVEN, Conn., May 8 /- VION ...nced the start of an investigator-sponsored,Phase ...loretazine(R),(VNP40101M) in combination with cyta...ed acute myelogenous leukemia (AML) and high-risk,...g conducted under the,direction of Ellen K. Ritchi...
(Date:5/8/2008)...Data Presentations to Focus on Use of Pro-Healing ...lerate Dual-Antiplatelet Therapy, HONG KONG, May ... both,a randomized pilot study and the real-world ... R stent, the world,s first pro-healing stent, wil... 2008 in Barcelona, Spain., The symposium, titled...
(Date:5/8/2008)...NGTON, Del., May 8 /- Astra...of a supplemental New Drug Application,(sNDA) to t...OQUEL XR(TM),(quetiapine fumarate) Extended-Releas...neralized anxiety disorder (GAD), including mainte...approval has been sought for an,atypical antipsych...
Breaking Medicine Technology:Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Depression and Alzheimers Risk Linked 16158 1Depression and Alzheimers Risk Linked 16158 2Depression and Alzheimers Risk Linked 16158 3War between the sexes begins before twins birth TAU researchers say 2794 1War between the sexes begins before twins birth TAU researchers say 2794 2U Iowa study finds biological link between pain and fatigue 2792 1U Iowa study finds biological link between pain and fatigue 2792 25W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 15W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 25W Public Relations Presents the 2008 Body Beautiful Media Symposium Benefiting The Skin Cancer Foundation 16157 3
... symptoms of SLE,disease at 52 Weeks and demonstra... weeks-, ROCKVILLE, Md., June 14, 2007 /PRNewswire...nnounced the presentation of Phase 2,trial data de...ficantly reduced disease activity across multiple ... quality of life in,patients with active systemic ...
...- CombinatoRx,Incorporated (NASDAQ: CRXX) today a...ed to its immuno-inflammatory product,candidates, ...t,Rheumatism (EULAR) Annual Congress of Rheumatolo... CRx-102 , In a poster entitled "Inhibition of Mac...CRx-102, a Novel Synergistic Combination,Drug Cand...
Other Medicine Technology:Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 2Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 3Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR 4
(Date:5/12/2008)...ONT, Calif., May 12 /PRNewswire/ -- Keck Graduate ...008, commencement ceremony will feature,the gradua...tudent, Eric,Tan, and the unveiling of KGI,s first... of Eric,s achievement in becoming the,first gradu..., KGI,s senior,vice president for academic affairs...
(Date:5/12/2008)... VA Nurses Are ,the Compassionate Heart, of System... The Department of,Veterans Affairs (VA), the nati...ional Nurses Week by honoring six of its top profe...rt of VA,s world-class health care,system," stated... "A great,deal of our reputation comes from the pe...
(Date:5/12/2008)... NASDAQ: CRME TSX: COM, VANCOUVER...Corp.,(NASDAQ: CRME / TSX: COM) today announced th...quarter of 2008 on the afternoon of Tuesday, May 1...and webcast at 4:30pm,Eastern (1:30pm Pacific) on ...onference call, please dial 416-641-6117 or,866-29...
(Date:5/12/2008)...lease is available in French . , Montreal, May...n that the administration of sildenafil protects t... This study was led by Dr. Christine Des Rosiers f...t Institute, in collaboration with Dr. Basil Petro...ty Health Centre (MUHC) and Dr. Christian Deschepp...
Breaking Medicine News(10 mins):Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2Health News:Cardiome To Release 2008 First Quarter Results 2Health News:Cardiome To Release 2008 First Quarter Results 3Health News:Cardiome To Release 2008 First Quarter Results 4Health News:New approach to protect the hearts of patients with muscular dystrophy 2Health News:New approach to protect the hearts of patients with muscular dystrophy 3
...rley Street plastic surgeon plans to sell a contro...de him and his wife “look years younger”.// He as... his memory and removed wrinkles, and made his wif... enough to be his daughter. The plastic surgeon a...
... respiratory specialists declared yesterday that c...million annually.// Lost of productivity when suf...n, while the health service industry loses ?104mil...itish Thoracic Society (BTS), this figure does not...
...y known as Mandrax, is a "downer" used to get reli...ide effects, however, have led to the banning of t...roduced in the 1960s into the pharmaceutical marke...was also used for other medicinal uses, especially...
... claimed to prevent more sudden deaths than defibr...ted defibrillators according to US scientists.// R... compared such preventive strategies by food suppl...n a computer-simulated community of 100,000 people...
Other Medicine News:Health News:Look younger with HGH!! 2Health News:Delhi Police Seized 4,400 kg of Banned Drug Mandrax 2
Level 1 enables hospitals to standardize all multiparameter patient monitors to a single temperature monitoring series. Our temperature monitoring disposale probes and reusable cables are superior in
Level 1 enables hospitals to standardize all multiparameter patient monitors to a single temperature monitoring series. Our temperature monitoring disposale probes and reusable cables are superior in
...tbeat. The bodys warmth beneath drapes. The life-g...ns are yours to guard, measure, stabilize and cros...roducts helps you do your job, giving you the info... precise management of your patients stability dur...
...aser system used in neurophysiology for studying e...just the amplitude and/or the duration of the stim...laser emission in an ongoing manner by acting on t...r include the high repeatability of the impulses, ...
Medicine Products: